MANGOCEUTICALS, INC.
No enriched coverage for $MGRX in the last 7 days.
No SEC Form 4 filings for $MGRX in the last 30 days.
See all $MGRX insider activity →Mangoceuticals (MGRX) announced a registered direct offering to raise $492,750 by selling 657,000 shares and warrants. The warrants are exercisable at $1.00 per share and expire in five years. Proceeds will be used for working capital and general corporate purposes, with the offering expected to close on Oct 9, 2026.
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX / October 9, 2026 / M
Mangoceuticals, Inc. (MGRX) completed a $500K direct offering at $0.75 per unit, a 74% premium over the referenced closing price. Each unit consists of one share and one warrant. The company filed details in an Oct. 9, 2026 Form 8-K. The offering is part of recent funding efforts, with potential catalysts including additional funding, warrant exercises, or revenue milestones.
Recent MGRX coverage spans corporate actions, financial news and macro economy.
The small capital raise may cause modest dilution and slight downward pressure on the stock.
The premium pricing may support short-term share price upside, but warrant dilution could cap gains.
The raise adds modest cash but high premium may cause short-term price pressure due to dilution concerns.
Negative reaction despite capital infusion to a subsidiary.
Nike Inc (NKE) reported Q1 revenue of $11.21B, missing estimates of $11.33B, but beat EPS estimates. Shares fell 9.5% in pre-market trading. Other stocks like Roze AI (RZAI) and Mangoceuticals (MGRX) also declined.
AlphAI scores every news story that mentions MGRX with an AI model for sentiment and relevance, and aggregates insider trades from MANGOCEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mangoceuticals (MGRX) announced a registered direct offering to raise $492,750 by selling 657,000 shares and warrants. The warrants are exercisable at $1.00 per share and expire in five years. Proceeds will be used for working capital and general corporate purposes, with the offering expected to close on Oct 9, 2026.
1 min readMANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX / October 9, 2026 / M
2 min readMangoceuticals, Inc. (MGRX) completed a $500K direct offering at $0.75 per unit, a 74% premium over the referenced closing price. Each unit consists of one share and one warrant. The company filed details in an Oct. 9, 2026 Form 8-K. The offering is part of recent funding efforts, with potential catalysts including additional funding, warrant exercises, or revenue milestones.
1 min readU.S. stock futures rose Friday after a weaker-than-expected September jobs report, with nonfarm payrolls adding 29,000 jobs vs. 90,000 expected. Nike (NKE) fell over 10% premarket after mixed earnings, while Synaptics (SYNA) surged 14.45% on an acquisition deal. The 10-year Treasury yield was at 5.24%, and markets priced in a 23.8% chance of a Fed rate hike in October.
3 min readNike Inc (NKE) reported Q1 revenue of $11.21B, missing estimates of $11.33B, but beat EPS estimates. Shares fell 9.5% in pre-market trading. Other stocks like Roze AI (RZAI) and Mangoceuticals (MGRX) also declined.
2 min readMangoceuticals' subsidiary MangoRx IP Holdings raised $2.5 million from two investors to commercialize its antiviral patent portfolio. The investment, paid in two tranches, gives investors a 25% stake in the subsidiary. The funds will support the development of MGX-0024, an antiviral technology with applications in animal and human health. The company's stock closed at $0.48 on Thursday, up 12.24%.
1 min readMangoceuticals (MGRX) shares dropped 12.24% after hours to $0.42 following a $2.5M investment in its former subsidiary, MangoRx IP Holdings. The investment, not involving MGRX stock, aims to advance commercialization. The company's market cap is $10.32M, with shares down 78.06% over the past year.
2 min readMangoceuticals (MGRX) announced a $2.5M investment in its subsidiary MangoRx IP Holdings, with $1.75M received upfront. The funds will support commercialization of its antiviral IP portfolio, targeting oral care and feed additives. The investment does not dilute MGRX's public shares.
2 min readMangoceuticals (MGRX) and Nuclea Energy mutually ended their business combination agreement on Aug 19, 2026, due to failing to secure $15 million in PIPE financing by the Aug 21 deadline. The termination is mutual, with no fees or breaches alleged.
1 min readMANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Business Combination Agreement with Nuclea Energy Inc. On August 19, 2026, Mangoceuticals, Inc. (the “Company” or “MGRX”) and Nuclea Energy Inc. (“Nuclea”) mutually agreed to terminate that certain Business
1 min read
